Doximity (DOCS) Cash & Equivalents (2021 - 2026)

Doximity (DOCS) has reported Cash & Equivalents for 6 consecutive years, with $273.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 99.33% year-over-year to $273.6 million in Q2 2026; TTM through Jun 2026 was $273.6 million, a 99.33% increase from a year earlier, with the FY2026 full-year figure at $219.2 million, up 4.56% from the prior year.
• Cash & Equivalents was $273.6 million for Q2 2026 at Doximity, up from $219.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $306.7 million in Q2 2023 and troughed at $64.8 million in Q4 2025.
• A 5-year average of $153.4 million and a median of $136.9 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 81.48% in 2022 and soared 178.61% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $136.5 million in 2022, then decreased by 9.79% to $123.1 million in 2023, then soared by 34.27% to $165.3 million in 2024, then sank by 60.77% to $64.8 million in 2025, then surged by 321.98% to $273.6 million in 2026.
• The last three Cash & Equivalents figures came in at $273.6 million (Q2 2026), $219.2 million (Q1 2026), and $64.8 million (Q4 2025), per Business Quant data.